Literature DB >> 17065974

Rational antidepressant selection: applying evidence-based medicine to complex real-world patients.

Mark Zetin1, Cara T Hoepner, Lynda Bjornson.   

Abstract

Every clinician faces the daily question of which antidepressant is best for a particular depressed patient. Double-blind studies submitted for U.S. Federal Drug Administration marketing approval include only the "purest" population of patients, and the American Psychiatric Association and other treatment guidelines often do not adequately address the complexities of developmental, family history, psychosocial, medical, and psychiatric comorbidity, and treatment-refractory issues that are seen in routine clinical practice. Long-term trends in depression treatment include ever-expanding choices among drugs, highly specific psychotherapies, and attempts to treat chronic and/or mild cases, with the goal of remission for all patients. We performed literature reviews and attempted to synthesize factors that may be useful in the application of evidence-based medicine in office-based psychiatric practice. We have found that factors influencing antidepressant selection include drug factors (including tolerability, interactions, and cost), depression subtype, psychiatric and medical comorbidity, and stage of life. In addition, patient preference for avoiding certain side effects and personal and family history of treatment response are helpful information. Most patients in the community would not fit strict antidepressant study criteria. Biologic markers predicting treatment response are not yet widely available, so the optimal choice of medication must be guided by detailed history.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065974

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  4 in total

Review 1.  Personalized medicine for depression: can we match patients with treatments?

Authors:  Gregory E Simon; Roy H Perlis
Journal:  Am J Psychiatry       Date:  2010-09-15       Impact factor: 18.112

Review 2.  Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice.

Authors:  Changsu Han; Sheng-Min Wang; Soo-Jung Lee; Tae-Youn Jun; Chi-Un Pae
Journal:  Chonnam Med J       Date:  2015-08-17

3.  Demographic and clinical factors associated with different antidepressant treatments: a retrospective cohort study design in a UK psychiatric healthcare setting.

Authors:  Andrea C Fernandes; David Chandran; Mizanur Khondoker; Michael Dewey; Hitesh Shetty; Rina Dutta; Robert Stewart
Journal:  BMJ Open       Date:  2018-09-05       Impact factor: 2.692

4.  Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future.

Authors:  Chiara Fabbri; Alessandro Serretti
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-02-29       Impact factor: 2.582

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.